Evaluation of the efficacy of paclitaxel with curcumin combination in ovarian cancer cells

Liu,Zeng; Zhu,Yuan-Yuan; Li,Zhao-Yuan; Ning,Si-Qing

doi:10.3892/ol.2016.5192

Evaluation of the efficacy of paclitaxel with curcumin combination in ovarian cancer cells

Authors:
- Zeng Liu
- Yuan-Yuan Zhu
- Zhao-Yuan Li
- Si-Qing Ning
View Affiliations

Affiliations: Department of Nuclear Medicine, Central Hospital of Xiangyang, Xiangyang, Hubei 441021, P.R. China, No. 1 Hospital of Xiangyang, Xiangyang, Hubei 441000, P.R. China
Published online on: September 26, 2016 https://doi.org/10.3892/ol.2016.5192
Pages: 3944-3948
Copyright: © Liu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to evaluate the efficacy of paclitaxel combined with curcumin (CUR) against drug resistance in ovarian cancer cells. PLGA-phospholipid-PEG nanoparticles were prepared using the nano precipitation method. The size and morphology of the nanoparticles were determined using a transmission electron microscope and particle size analyzer. The encapsulation efficiency of nanoparticles was determined using the ultrafiltration centrifugation method. The dialysis method was used to study the release of PLGA-phospholipid-PEG nanoparticles. ADM was used to induce the A2780 cell line (human ovarian cancer cell line) to establish the model of the multidrug-resistant (MDR) cell line, and the protein activity of P-glycoprotein (P-gp) in the A2780 cell line and A2780/ADM resistant cell line was determined using western blot analysis. The results showed that, the prepared nanoparticles were uniform in size, with a size of approximately 100 nm, and round in shape. Additionally, the nanoparticles had a more gentle and slow release than the free drug release. The results of the protein trace printing experiment showed that the P-gp content of the drug‑resistant cell line was significantly reduced by the CUR nanoparticles. In conclusion, PLGA-phospholipid nanoparticles containing taxol and CUR have improved solubility and stability together with a slow release effect. In addition, CUR was able to overcome the MDR of tumor cells by elevating the paclitaxel concentration in the tumor cells to improve the antitumor activity of this combination.

View Figures

View References

1	Anton-Culver H, Cohen PF, Gildea ME and Ziogas A: Characteristics of BRCA1 mutations in a population-based case series of breast and ovarian cancer. Eur J Cancer. 36:1200–1208. 2000. View Article : Google Scholar : PubMed/NCBI
2	Bell DA: Origins and molecular pathology of ovarian cancer. Mod Pathol. 18(Suppl 2): S19–S32. 2005. View Article : Google Scholar : PubMed/NCBI
3	Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT, Turco M, Caputo R, Bergin P, Greenberg J, et al: TAXUS-IV Investigators: A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med. 350:221–231. 2004. View Article : Google Scholar : PubMed/NCBI
4	Duvoix A, Blasius R, Delhalle S, Schnekenburger M, Morceau F, Henry E, Dicato M and Diederich M: Chemopreventive and therapeutic effects of curcumin. Cancer Lett. 223:181–190. 2005. View Article : Google Scholar : PubMed/NCBI
5	Fojo A, Hamilton TC, Young RC and Ozols RF: Multidrug resistance in ovarian cancer. Cancer. 60(Suppl 8): 2075–2080. 1987. View Article : Google Scholar : PubMed/NCBI
6	Gillet JP, Efferth T and Remacle J: Chemotherapy-induced resistance by ATP-binding cassette transporter genes. Biochim Biophys Acta. 1775:237–262. 2007.PubMed/NCBI
7	Shaffer BC, Gillet JP, Patel C, Baer MR, Bates SE and Gottesman MM: Drug resistance: still a daunting challenge to the successful treatment of AML. Drug Resist Updat. 15:62–69. 2012. View Article : Google Scholar : PubMed/NCBI
8	Nabekura T, Yamaki T, Hiroi T, Ueno K and Kitagawa S: Inhibition of anticancer drug efflux transporter P-glycoprotein by rosemary phytochemicals. Pharmacol Res. 61:259–263. 2010. View Article : Google Scholar : PubMed/NCBI
9	Duncan R: Polymer conjugates as anticancer nanomedicines. Nat Rev Cancer. 6:688–701. 2006. View Article : Google Scholar : PubMed/NCBI
10	Panyam J, Sahoo SK, Prabha S, Bargar T and Labhasetwar V: Fluorescence and electron microscopy probes for cellular and tissue uptake of poly(D, L-lactide-co-glycolide) nanoparticles. Int J Pharm. 262:1–11. 2003. View Article : Google Scholar : PubMed/NCBI
11	van Vlerken LE and Amiji MM: Multi-functional polymeric nanoparticles for tumour-targeted drug delivery. Expert Opin Drug Deliv. 3:205–216. 2006. View Article : Google Scholar : PubMed/NCBI
12	Kumari A, Yadav SK and Yadav SC: Biodegradable polymeric nanoparticles based drug delivery systems. Colloids Surf B Biointerfaces. 75:1–18. 2010. View Article : Google Scholar : PubMed/NCBI
13	Alexis F, Pridgen E, Molnar LK and Farokhzad OC: Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol Pharm. 5:505–515. 2008. View Article : Google Scholar : PubMed/NCBI
14	Baratchi S, Kaur RK, Khoshmanesh K, Vasu P, Ashok C, Hittu M, Paratt A, Krishnakumar S, Sun X, Sahoo SK, et al: Promises of nanotechnology for drug delivery to brain in neurodegenerative diseases. Curr Nanosci. 5:15–25. 2009. View Article : Google Scholar
15	Parveen S and Sahoo SK: Nanomedicine: Clinical applications of polyethylene glycol conjugated proteins and drugs. Clin Pharmacokinet. 45:965–988. 2006. View Article : Google Scholar : PubMed/NCBI
16	Ong AT, Serruys PW, Aoki J, Hoye A, van Mieghem CA, Rodriguez-Granillo GA, Valgimigli M, Sonnenschein K, Regar E, van der Ent M, et al: The unrestricted use of paclitaxel- versus sirolimus-eluting stents for coronary artery disease in an unselected population: one-year results of the Taxus-Stent Evaluated at Rotterdam Cardiology Hospital (T-SEARCH) registry. J Am Coll Cardiol. 45:1135–1141. 2005. View Article : Google Scholar : PubMed/NCBI
17	Daemen J, Wenaweser P, Tsuchida K, Abrecht L, Vaina S, Morger C, Kukreja N, Jüni P, Sianos G, Hellige G, et al: Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet. 369:667–678. 2007. View Article : Google Scholar : PubMed/NCBI
18	Stone GW, Midei M, Newman W, Sanz M, Hermiller JB, Williams J, Farhat N, Mahaffey KW, Cutlip DE, Fitzgerald PJ, et al: SPIRIT III Investigators: Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: a randomized trial. JAMA. 299:1903–1913. 2008. View Article : Google Scholar : PubMed/NCBI
19	Bierhaus A, Zhang Y, Quehenberger P, Luther T, Haase M, Müller M, Mackman N, Ziegler R and Nawroth PP: The dietary pigment curcumin reduces endothelial tissue factor gene expression by inhibiting binding of AP-1 to the DNA and activation of NF-kappa B. Thromb Haemost. 77:772–782. 1997.PubMed/NCBI
20	Aggarwal S, Ichikawa H, Takada Y, Sandur SK, Shishodia S and Aggarwal BB: Curcumin (diferuloylmethane) down-regulates expression of cell proliferation and antiapoptotic and metastatic gene products through suppression of IkappaBalpha kinase and Akt activation. Mol Pharmacol. 69:195–206. 2006.PubMed/NCBI